Skip to content
PubMed This is a summary of 11 peer-reviewed journal articles Updated
Cardiology · Heart Failure

Can You Stop Heart Failure Medications After EF Improves?

At a Glance

Even when ejection fraction returns to normal, heart failure is often in remission rather than permanently cured. Most medicines that protect the heart should continue long term because stopping them can cause a silent relapse; adjust treatment only with a cardiologist.

In most cases, you should not stop taking your core congestive heart failure medications even if your ejection fraction (EF)—the percentage of blood your heart pumps out with each beat—improves or returns to normal. Current medical guidelines strongly recommend continuing these disease-modifying therapies indefinitely [1][2].

It is important to distinguish between two types of heart failure medicines:

  • Disease-modifying therapies: Medications like beta-blockers, ACE inhibitors/ARBs/ARNIs, MRAs (like spironolactone), and SGLT2 inhibitors protect your heart muscle. These are the medications guidelines say to continue [1].
  • Diuretics (water pills): These are mainly used to relieve symptoms of fluid buildup. If you no longer have congestion, your doctor might reduce or stop your diuretic, but this does not mean it is safe to stop your disease-modifying therapies.

An improved EF is excellent news, but it typically means your heart is in a state of remission rather than being permanently cured [3]. Stopping your core medications significantly increases the risk that your heart failure will return, and this can happen before you even begin to feel symptoms again [4][5].

Understanding Remission vs. Recovery

When your previously reduced EF goes up—often to above 40%—doctors refer to this as Heart Failure with improved Ejection Fraction (HFimpEF) [6]. While your heart’s pumping ability looks better on an echocardiogram (an ultrasound of the heart) and you may feel completely normal, the underlying vulnerability for heart failure usually remains [3][7].

The medications you are taking are actively protecting your heart and maintaining this improved state. Continued treatment helps protect the improvement, and stopping the medications removes that protection.

The Evidence Against Stopping

A landmark study known as the TRED-HF trial tested what happens when patients with a specific type of heart failure (recovered dilated cardiomyopathy) slowly stopped their medications under close medical supervision [4]. These patients had no symptoms, normal EF (above 50%), and normal heart failure blood markers (like NT-proBNP).

The results showed a high risk of relapse:

  • Within just six months, 44% of the patients who stopped their medications experienced a relapse, compared to 0% of those who continued taking them [4].
  • When researchers followed these same patients for about six years, 65% eventually relapsed [8].
  • A review of three prospective studies (involving 133 patients with recovered dilated cardiomyopathy) confirmed that stopping medications was associated with significantly higher odds of relapse compared to continuing them [9].

While this exact risk may vary depending on what originally caused your heart failure (such as coronary artery disease or a viral infection), the overarching finding is clear: relapses are common. Furthermore, relapses often start silently. A patient’s heart rate and blood pressure often rose, and the heart muscle began to weaken again weeks before they felt symptoms or showed changes in their lab work [5][10].

When Might Medicine Changes Be Considered?

There are specific situations where a cardiologist might carefully adjust your medications:

  • Pregnancy: Several core heart failure medications can be unsafe during pregnancy. If you are planning to become pregnant or have a positive pregnancy test, do not stop your medications on your own. Contact your cardiology and obstetric teams immediately to safely transition to alternative treatments.
  • Resolved Underlying Causes: If your heart failure was caused by a specific issue that has been fully treated—such as correcting an abnormal heart rhythm—a doctor might consider adjusting medications [1][11]. However, a corrected rhythm is not an automatic exception, and guidelines generally still favor continued therapy [1].
  • Severe Side Effects or Changing Health: Medication doses might need adjustment if you experience dangerously low blood pressure, kidney function problems, or severe side effects.

How Changes Are Made and What to Watch For

If you and your doctor decide a medication must be changed, they will create a specific plan. For example, some drugs (like beta-blockers) require careful tapering and cannot be stopped abruptly. Your doctor will likely schedule follow-up blood work (to check kidney function and potassium), blood pressure checks, and imaging [7].

Even with an improved EF, you should monitor for early warning signs of a relapse. Contact your care team if you notice:

  • New or worsening breathlessness
  • Needing to sleep propped up on extra pillows
  • Unexplained, rapid weight gain
  • Swelling in your legs, ankles, or abdomen
  • Unusual fatigue or dizziness

Common questions in this guide

Is it safe to stop heart failure medicine if my ejection fraction is normal?
Usually, no. An improved or normal ejection fraction often reflects remission rather than a permanent cure, and stopping medicines that protect the heart can allow heart failure to return. Talk with your cardiologist before changing any dose.
Can my water pill be stopped after my ejection fraction improves?
Sometimes, if you no longer have fluid buildup or congestion, a clinician may lower or stop a diuretic, also called a water pill. This is different from stopping medicines such as beta-blockers, ACE inhibitors, ARBs, ARNIs, MRAs, or SGLT2 inhibitors, which help protect the heart. Make any change only with your care team.
How often does heart failure return after medicines are withdrawn?
In the TRED-HF study of people with recovered dilated cardiomyopathy, 44% had a relapse within six months after supervised medication withdrawal. During follow-up of about six years, 65% eventually relapsed. Risk can vary by the original cause of heart failure, but relapse may begin before symptoms appear.
What if side effects, kidney problems, or pregnancy make my medicines unsafe?
Do not stop heart failure medicines on your own. Contact your cardiology team promptly if you are pregnant, planning a pregnancy, have very low blood pressure, kidney problems, or severe side effects so they can adjust doses or choose safer alternatives. Some medicines, including beta-blockers, may need to be tapered rather than stopped suddenly.
How will my doctor monitor me if a heart failure medicine is changed?
Your care team may check blood pressure, kidney function, and potassium and repeat an echocardiogram or other heart imaging. Some medicines require a gradual dose reduction, and monitoring may detect a relapse before you feel symptoms. Report new breathlessness, needing extra pillows, rapid weight gain, swelling, fatigue, or dizziness.

Get notified when new evidence is published on congestive heart failure.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (11)
  1. 1

    Management of Heart Failure With Improved Ejection Fraction: Current Evidence and Controversies.

    Kodur N, Tang WHW

    JACC. Heart failure 2025; (13(4)):537-553 doi:10.1016/j.jchf.2025.02.007.

    PMID: 40204384
  2. 2

    Heart Failure Management in 2023: A Pharmacotherapy- and Lifestyle-Focused Comparison of Current International Guidelines.

    MacDonald BJ, Virani SA, Zieroth S, Turgeon R

    CJC open 2023; (5(8)):629-640 doi:10.1016/j.cjco.2023.05.008.

    PMID: 37720183
  3. 3

    Heart Failure With Improved Ejection Fraction: Is it Possible to Escape One's Past?

    Gulati G, Udelson JE

    JACC. Heart failure 2018; (6(9)):725-733 doi:10.1016/j.jchf.2018.05.004.

    PMID: 30098965
  4. 4

    Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial.

    Halliday BP, Wassall R, Lota AS, et al.

    Lancet (London, England) 2019; (393(10166)):61-73 doi:10.1016/S0140-6736(18)32484-X.

    PMID: 30429050
  5. 5

    Changes in clinical and imaging variables during withdrawal of heart failure therapy in recovered dilated cardiomyopathy.

    Halliday BP, Owen R, Gregson J, et al.

    ESC heart failure 2022; (9(3)):1616-1624 doi:10.1002/ehf2.13872.

    PMID: 35257498
  6. 6

    Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association.

    Bozkurt B, Coats AJS, Tsutsui H, et al.

    European journal of heart failure 2021; (23(3)):352-380 doi:10.1002/ejhf.2115.

    PMID: 33605000
  7. 7

    Heart failure improvement, remission, and recovery: A European Journal of Heart Failure expert consensus document.

    Hulot JS, Ter Maaten JM, Bayes-Genis A, et al.

    European journal of heart failure 2025; (27(10)):1807-1819 doi:10.1002/ejhf.3732.

    PMID: 40533420
  8. 8

    Long-term follow-up of the TRED-HF trial: Implications for therapy in patients with dilated cardiomyopathy and heart failure remission.

    Cheng L, Hammersley D, Ragavan A, et al.

    European journal of heart failure 2025; (27(1)):113-123 doi:10.1002/ejhf.3475.

    PMID: 39349993
  9. 9

    Withdrawal versus continuation of guideline-directed medical therapy in heart failure with improved ejection fraction: a systematic review and meta-analysis.

    Jaramillo JCH, Muñoz JES, Arroyo MCO, et al.

    Romanian journal of internal medicine = Revue roumaine de medecine interne 2026; (64(3)):173-182 doi:10.2478/rjim-2026-0015.

    PMID: 42487279
  10. 10

    Heart Rate as a Marker of Relapse During Withdrawal of Therapy in Recovered Dilated Cardiomyopathy.

    Halliday BP, Vazir A, Owen R, et al.

    JACC. Heart failure 2021; (9(7)):509-517 doi:10.1016/j.jchf.2021.03.010.

    PMID: 34119469
  11. 11

    Withdrawal of heart failure therapy after atrial fibrillation rhythm control with ejection fraction normalization: the WITHDRAW-AF trial.

    Segan L, Kistler PM, Nanayakkara S, et al.

    European heart journal 2026; (47(2)):250-262 doi:10.1093/eurheartj/ehaf563.

    PMID: 40830055

This page explains why heart failure medicines are often continued after ejection fraction improves for informational purposes only and is not medical advice. Do not stop or change a medicine without speaking with your cardiologist or care team.